Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
EDP-305 1 mg
ENANTA PHARMACEUTICALS INC
Primary Biliary Cholangitis
1 trial -
EDP-305 1.5 mg
ENANTA PHARMACEUTICALS INC
Non-Alcoholic Steatohepatitis
1 trial -
EDP-305 Dose 1
ENANTA PHARMACEUTICALS INC
Non-Alcoholic Steatohepatitis
1 trial -
EDP-323 Dose Regimen 1
ENANTA PHARMACEUTICALS INC
RSV Infection
1 trial -
EDP-420 / Duration of Treatment - 3 days
ENANTA PHARMACEUTICALS INC
Community Acquired Pneumonia
1 trial -
EDP-938
ENANTA PHARMACEUTICALS INC
Respiratory Syncytial Virus
1 trial -
EDP-938
ENANTA PHARMACEUTICALS INC
Respiratory Syncytial Virus Infections
1 trial -
EDP-938
ENANTA PHARMACEUTICALS INC
Respiratory Syncytial Virus (RSV)
2 trials -
EDP-938
ENANTA PHARMACEUTICALS INC
RSV Infection
6 trials -
EDP-938 Dose 1
ENANTA PHARMACEUTICALS INC
RSV Infection
1 trial -
EDP-938, EDP-938 Placebo tablets
ENANTA PHARMACEUTICALS INC
Respiratory syncytial virus (RSV)
1 trial -
EGF816, EGF816, LEE011, LEE011
Novartis Pharmaceuticals
Different types of advanced cancer
1 trial -
EGF816, INC280, EGF816, GEFITINIB, INC280, EGF816
Novartis Pharmaceuticals
cMET-dependent malignancies
1 trial -
ELX-02
Eloxx Pharmaceuticals
Cystic Fibrosis
2 trials -
ELX-02
Eloxx Pharmaceuticals
Alport Syndrome
1 trial -
ELX-02
Eloxx Pharmaceuticals
Genetic Disease
2 trials -
ENMD-2076
CASI Pharmaceuticals
Advanced Adult Hepatocellular Carcinoma
1 trial -
ENMD-2076
CASI Pharmaceuticals
Ovarian Cancer
1 trial -
ENMD-2076
CASI Pharmaceuticals
Triple Negative Breast Cancer
1 trial -
ENTECAVIR , Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe, TENOFOVIR DISOPROXIL , TENOFOVIR ALAFENAMIDE , -, VAY736
Novartis Pharmaceuticals
Diffuse cutaneous systemic sclerosis (dcSSc)
1 trial -
EP-104GI
EUPRAXIA PHARMACEUTICALS INC.
Eosinophilic Esophagitis
1 trial -
EP-104IAR 25 mg
EUPRAXIA PHARMACEUTICALS INC.
Osteoarthritis, Knee
1 trial -
EP0062, ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets
Lacuna Pharma Pty Ltd
Breast Cancer
1 trial -
EPI-321
Biotech Pharmaceutical Co.,
Facioscapulohumeral Muscular Dystrophy
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources